Disclosures

California

California

Vermont

Vermont

Introduction

Gilead believes that there is strength through partnership. Collaborations of all kinds - with partners in science, academia, business and local communities - are central to our work. Partnerships enhance our ability to develop innovative medicines and deliver them to people as efficiently as possible.

Healthcare professionals, other relevant decision makers and healthcare organizations with whom we work provide valuable, independent and expert knowledge derived from their clinical and management experience. This expertise makes an important contribution to our efforts to improve the quality of patient care, with benefits for individuals and society at large. We believe healthcare professionals, other relevant decision makers and healthcare organizations should be fairly compensated for the legitimate expertise and services they provide.

We are fully committed to compliance with healthcare spend transparency requirements which require disclosure of payments and transfers of value made to healthcare professionals, other relevant decision makers and healthcare organizations. We believe this is the right approach for industry and enhances stakeholder trust.

In line with local Transparency Reporting requirements, Gilead is disclosing its interactions with HealthCare Professionals and HealthCare Organizations in the following reports for European countries, supported by either the Gilead EFPIA Methodological Note or by a locally adapted one. 

Enquiries about any of these reports should be directed here.

Belgium

In line with the Sunshine Act  and the Royal Decree of execution of 14 June 2017, transfers for value made to HCPs, HCOs and Patient Organizations  based in Belgium, are uploaded on www.betransparent.be on or around 31st of May covering  the previous calendar year. R&D spend is disclosed on www.betransparent.be on or around 30th of June covering the previous calendar year as well.

Enquiries about the disclosed transfers of value should be directed here.

Get more information about Gilead operations in Belgium

France

In accordance with the terms of the French law on transparency of links between industries and professionals of the healthcare sector, Gilead Sciences discloses data on benefits (including remunerations) granted to the categories of persons and entities covered by law, as well as information relating to the agreements concluded with these same persons and entities.

Disclosure information in France is published on the DGS (Department of the Ministry of Health) National Public Platform:

  • By 1st September of each year for the benefits granted during the first half of the year
  • By 1st March of each year for the benefits granted during the second half of the preceding year

Click here to access the Public Transparency database https://www.transparence.sante.gouv.fr

Ireland

In line with the Irish Pharmaceutical Healthcare Association code, transfers for value made to HCPs, HCOs based in Ireland, are uploaded on https://www.transferofvalue.ie on or around 30 of June covering the previous calendar year.

Enquiries about the disclosed transfers of value should be directed here.

Netherlands

In line with the Commissie Geneesmiddelen Reclame (CGR) code, transfers for value made to HCPs, HCOs and Patient Organizations based in Netherlands, are uploaded on www.transparantieregister.nl on or around 31st of May covering the previous calendar year.

R&D spend is disclosed in aggregate on the affiliate’s web page.

Enquiries about the disclosed transfers of value should be directed here.

Portugal

In line with our obligations to disclose payments and transfers of value, disclosure information in Portugal is disclosed in the Portuguese Medicines Agency transparency platform (Plataforma de Comunicações - Transparência e Publicidade do INFARMED) within 30 days of payment or transfer of value date. Click here to access the platform. To access the disclosed information, insert “Gilead Sciences.” General enquiries about the disclosure should be directed here.

Slovakia

As of 2016, in line with our legal obligations to disclose payments and transfers of value, disclosure information in Slovakia is published on the National Health Information Center platform nczisk.sk every 6 months. Click here to see reports. Enquiries about the disclosed transfers of value should be directed here.

Spain

The Spanish company Gilead Sciences, S.L.U. ("Gilead") is adhered to the Code of Good Practices of the Pharmaceutical Industry of Farmaindustria (the "Code").

Pursuant to the Code, Gilead is disclosing its interactions with Spanish HealthCare Professionals and HealthCare Organisations in the following report, supported by a methodological note.

The publication of this report does not authorize you to process any personal data beyond the purposes set forth in the Code (e.g., cross-check of information published by other companies bound by the Code). Gilead has adopted the appropriate security measures to prevent the indexing of information through search engines.

Any enquiries about the report should be directed here.

Get more information about Gilead operations in Spain

Turkey

In line with our obligations to disclose transfers of value, for both HCPs and HCOs disclosure information in Turkey is made on to the Turkish Ministry of Health disclosure platform annually before 30th of June covering the previous calendar year. Transfers of value made by Gilead to patient organizations are listed here.

United Kingdom

In line with our obligations to disclose payments and transfers of value, disclosure information in the U.K. is published on the ABPI Disclosure platform annually on or around the 30th of June covering the previous calendar year. Click here to access the report. General enquiries about the reports should be directed here.

Get more information about Gilead operations in United Kingdom